Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
T. Rowe Price Associates, Inc. reports beneficial ownership of 5,461,988 shares of Vera Therapeutics common stock, representing 7.7% of the class as of December 31, 2025. It has sole voting power over 5,376,319 shares and sole dispositive power over 5,461,976 shares, with no shared voting or dispositive power.
The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young received new equity awards. On February 4, 2026, he was granted 10,000 shares of Class A Common Stock in the form of restricted stock units at $0 per share, bringing his directly held stock to 67,839 shares.
He was also granted stock options for 20,000 shares of Class A Common Stock at an exercise price of $42.74 per share, all held directly. The RSUs vest in four equal annual installments each February 20 from 2027 through 2030, while the options vest over 48 months starting March 4, 2026, subject to his continued service.
Vera Therapeutics President and CEO Fordyce Marshall reported new equity awards tied to continued service. On February 4, 2026, he received 68,800 RSUs of Class A common stock at no cost under the 2021 Equity Incentive Plan, vesting in four equal annual installments each February 20 from 2027 through 2030.
He was also granted a stock option for 137,500 shares of Class A common stock at an exercise price of $42.74 per share, with 1/48 vesting on March 4, 2026 and the remainder vesting monthly thereafter. Following these awards, Marshall reports 274,088 Class A shares held directly, plus indirect holdings of 122,949 shares through a GRAT and 99,081 shares through The Fordyce Revocable Trust.
Vera Therapeutics’ chief financial officer Sean Grant received new equity awards in the form of restricted stock units and stock options. On February 4, 2026, he was granted 25,000 RSUs tied to Class A Common Stock and a stock option for 50,000 shares at an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, subject to continued service. The option vests over four years, beginning March 4, 2026, with monthly vesting thereafter, also conditioned on continued service. Following this grant, Grant directly holds 119,130 Class A shares plus 50,000 options, and 5,000 additional shares are held indirectly through a trust.
Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported new equity awards. On February 4, 2026, he received 20,000 shares of Class A Common Stock for $0, representing restricted stock units granted under Vera’s 2021 Equity Incentive Plan. After this award, he directly owned 65,800 Class A shares.
He was also granted a stock option for 40,000 shares of Class A Common Stock at an exercise price of $42.74 per share. One forty-eighth of the option vests on March 4, 2026, with the remainder vesting in equal monthly installments, while the RSUs vest in four equal annual installments each February 20 from 2027 through 2030, all subject to continued service.
Vera Therapeutics Chief Regulatory Officer receives new equity awards. William D. Turner was granted 25,000 restricted stock units (RSUs) of Class A Common Stock and a stock option covering 50,000 shares. The option has a $42.74 exercise price and was granted for no cash consideration.
One-fourth of the RSUs vest on each of February 20, 2027, 2028, 2029 and 2030, if he remains in service. The option vests in 48 equal monthly installments, starting March 4, 2026, also subject to continued service. After these grants, he directly holds 47,500 Class A shares and 50,000 options.
Vera Therapeutics Chief Operating Officer receives new equity awards. On February 4, 2026, David Lee Johnson was granted 20,000 restricted stock units of Class A Common Stock at a price of $0 under Vera’s 2021 Equity Incentive Plan and 40,000 stock options with an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, assuming continued service. The stock options begin vesting on March 4, 2026, with 1/48th of the grant vesting monthly, also conditioned on continued service. Following the RSU grant, he beneficially owns 48,306 Class A shares directly.
Vera Therapeutics Chief Medical Officer granted RSUs and stock options
Vera Therapeutics’ Chief Medical Officer, Robert Brenner, reported equity awards dated February 4, 2026. He received 25,000 shares of Class A common stock in the form of restricted stock units, granted at $0 cost. These RSUs vest in four equal annual installments on February 20, 2027, 2028, 2029 and 2030, if he remains in continuous service.
He also received a stock option for 50,000 shares of Class A common stock at an exercise price of $42.74 per share, expiring on February 3, 2036. One forty‑eighth of the option vests on March 4, 2026, with the remainder vesting monthly thereafter, subject to continued service. After these transactions, Brenner directly beneficially owns 53,098 shares of Class A common stock.
FMR LLC and Abigail P. Johnson reported their holdings of Vera Therapeutics Inc. Class A common stock on an amended Schedule 13G. They report beneficial ownership of 2,885,853 shares, representing 4.1% of the class.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. FMR LLC has sole voting power over 2,878,610 shares and sole dispositive power over 2,885,853 shares, while Abigail P. Johnson reports sole dispositive power over the same 2,885,853 shares.
Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.
He also holds stock options for 60,000 shares at an exercise price of $41.75 expiring on 10/01/2034 and 31,500 shares at $29.18 expiring on 02/17/2035. These options vest monthly over time, following initial partial vesting completed in January 2026.